Anavex Life Sciences to Initiate Phase 2 Study of ANAVEX®2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX®2-73 in Rett Syndrome
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018
Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical Hypertension
Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs
